Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline

Affiliations

¹ Department of Haematology, Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
² Department of Haematology, Nottingham University Hospitals NHS Foundation Trust, Oxford, UK.
³ Translational Medical Sciences, University of Nottingham, Nottingham, UK.
⁴ Department of Haematology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK.
⁵ Department of Haematology, University College London Hospitals, London, UK.
⁶ Department of Haematology, King's College Hospital, London, UK.
⁷ Department of Cellular Pathology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
⁸ Department of Haematology, The Royal Marsden Hospital, London, UK.
⁹ Department of Haematology, Derriford Hospital, Plymouth, UK.
¹⁰ Department of Haematology, The Christie NHS Foundation Trust, Manchester, UK.
¹¹ Beatson West of Scotland Cancer Centre, Glasgow, UK.

Toby A Eyre et al. Br J Haematol. 2024 Jan.

. 2024 Jan;204(1):108-126.

doi: 10.1111/bjh.19131. Epub 2023 Oct 25.

¹ Department of Haematology, Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
² Department of Haematology, Nottingham University Hospitals NHS Foundation Trust, Oxford, UK.
³ Translational Medical Sciences, University of Nottingham, Nottingham, UK.
⁴ Department of Haematology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK.
⁵ Department of Haematology, University College London Hospitals, London, UK.
⁶ Department of Haematology, King's College Hospital, London, UK.
⁷ Department of Cellular Pathology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
⁸ Department of Haematology, The Royal Marsden Hospital, London, UK.
⁹ Department of Haematology, Derriford Hospital, Plymouth, UK.
¹⁰ Department of Haematology, The Christie NHS Foundation Trust, Manchester, UK.
¹¹ Beatson West of Scotland Cancer Centre, Glasgow, UK.

No abstract available

Keywords: MCL; lymphomas; mantle cell lymphoma; non-Hodgkin lymphoma.

Comment in

Letting the mantle out of the bag.
Visco C. Visco C. Br J Haematol. 2024 Jan;204(1):11-13. doi: 10.1111/bjh.19137. Epub 2023 Oct 25. Br J Haematol. 2024. PMID: 37880826

1. Hadzidimitriou A, Agathangelidis A, Darzentas N, Murray F, Delfau-Larue MH, Pedersen LB, et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood. 2011;118(11):3088-3095.
1. Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72(20):5307-5316.
1. Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101(12):4975-4981.
1. Jain P, Wang ML. Mantle cell lymphoma in 2022-a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022;97(5):638-656.
1. Swerdlow SH, Campo E, Pileri SA, Lee Harris N, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.